Objective: To investigate the efficacy and safety of the integrated traditional Chinese and Western medicine therapy with Biling Weitong Granules in combination with conventional Western medicine quadruple or triple therapy compared to traditional Western medicine therapy for eradicating Helicobacter pylori (H.pylori). Methods: PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure, Wanfang Database and Sinomed were searched, and the randomized controlled studies about the application of Biling Weitong Granule for eradicating H.pylori eradication were collected. The retrieval period was from the establishment of the database to November 2022. Data extraction and literature quality evaluation were performed on the retrieved literature according to the Cochrane system evaluation method. Meta-analysis was performed using RevMan 5.4 software. Results: A total of 4 articles and 506 patients were included. The results of Meta-analysis showed that the eradication rate of H.pylori in the experimental group was higher than that in the control group (OR=4.18, 95%CI: 2.57-6.79, I2=0%, P＜0.00001). In terms of safety, the incidence of adverse reactions in the experimental group was lower than that in the control group (OR=0.30, 95%CI: 0.10-0.85, I2=0%, P=0.02). Conclusion: The integrated traditional and Western medicine treatment regimen with Biling Weitong Granules is significantly better than the western medicine quadruple and triple therapy in terms of efficacy and safety.
MENG Zhiyi
,
MENG Xianmei
,
LIU Feifei
,
ZHANG Jingjie
,
NIAN Yuanyuan
,
WANG Chi
. Meta-analysis of integrated traditional Chinese and Western medicine therapy with Biling Weitong Granules in the treatment of Helicobacter pylori infection[J]. Journal of Baotou Medical College, 2024
, 40(6)
: 56
-60
.
DOI: 10.16833/j.cnki.jbmc.2024.06.010
[1] 中华医学会消化病学分会幽门螺杆菌和消化性溃疡学组,全国幽门螺杆菌研究协作组,刘文忠,等. 第五次全国幽门螺杆菌感染处理共识报告[J]. 胃肠病学,2017,22(6):346-360.
[2] 全国中西医整合幽门螺杆菌处理共识专家组. 全国中西医整合治疗幽门螺杆菌相关"病-证"共识[J]. 中华医学杂志,2018,98(26):2066-2072.
[3] 刘敏.荜铃胃痛颗粒的基础研究及临床应用[J]. 中国中西医结合消化杂志,2018,26(7):553-556.
[4] 白璐,高睿. 荜铃胃痛颗粒联合泮托拉唑四联方案对治疗慢性胃炎合并幽门螺杆菌感染患者的疗效及安全性观察[J]. 贵州医药,2021,45(11):1716-1717.
[5] 戴硙,姚玉玲,周莹乔. 荜铃胃痛颗粒联合兰索拉唑四联方案治疗慢性胃炎合并幽门螺杆菌感染患者的疗效研究[J]. 现代消化及介入诊疗,2020,25(4):515-517.
[6] 郭佳宇,王晓瑜. 荜铃胃痛颗粒联合四联疗法对气滞血瘀型幽门螺杆菌相关性胃炎疗效观察[J]. 药物流行病学杂志,2020,29(7):465-468.
[7] 姚鹏,康洪昌,王江,等. 荜铃胃痛颗粒联合三联疗法治疗慢性萎缩性胃炎合并幽门螺杆菌感染的临床研究[J]. 天津中医药,2021,38(9):1138-1143.
[8] Malfertheiner P, Venerito M, Schulz C. Helicobacter pylori infection: new facts in clinical management[J]. Curr Treat Options Gastroenterol, 2018, 16(4):605-615.
[9] 王立民,曹瑞珍,田字彬,等. 调整铋剂四联疗法联合益生菌根治幽门螺杆菌的临床观察[J]. 中国现代医生,2023,61(31):13-16,25.
[10] 郝科欣,邓涛. 铋剂四联方案与高剂量双联方案治疗幽门螺杆菌感染的对比研究进展[J]. 中华消化杂志,2023,43(5):344-347.
[11] Qian J, Ye F, Zhang J, et al. Levofloxacin-containing triple and sequential therapy or standard sequential therapy as the first line treatment for Helicobacter pylori eradication in China[J]. Helicobacter, 2012 , 17(6):478-485.
[12] 胡伏莲. 幽门螺杆菌感染治疗的新路径[J]. 中华医学杂志,2012,92(10):649-651.
[13] 李仕宇,彭丹若,蒲紫鹃. 黄连素辅助根除幽门螺杆菌感染的有效性及安全性的meta分析[J]. 中国医药科学,2021,11(21):70-74.
[14] 吕宾. 中药和胃黏膜保护剂在幽门螺杆菌根除治疗中的作用[J]. 中华消化杂志,2022,42(11):741-744.
[15] 刘绍能,刘正新,孟淼,等. 摩罗丹配合雷贝拉唑三联疗法治疗幽门螺杆菌相关慢性胃炎疗效观察[J]. 现代中西医结合杂志,2017,26(7):749-751.
[16] 张天龙,赵继荣,陈祁青,等. 延胡索化学成分及镇痛作用机制研究进展[J]. 中国中医药信息杂志,2021,28(5):141-144.
[17] 刘麟,李京生,鞠海. 海螵蛸在制酸止痛应用中不同服药方式验案举隅[J]. 中国民族民间医药,2018,27(2):82-84.
[18] 邓远辉,刘瑜彬,罗淑文,等. α-香附酮的分离及其解热镇痛作用研究[J]. 中药新药与临床药理,2012,23(6):620-623.
[19] 刘玲丽,周紫芳,胡婕妤,等. 大黄蒽醌类化合物抑菌作用研究进展[J]. 杭州师范大学学报(自然科学版),2021,20(1):54-58.
[20] Xie F, Zhang M, Zhang CF, et al. Anti-inflammatory and analgesic activities of ethanolic extract and two limonoids from Melia toosendan fruit[J]. J Ethnopharmacol, 2008, 22,117(3):463-466.
[21] 杨慧,刘晓凤,刘钱,等. Q-marker思路下的黄连花薹抗菌作用及机制研究[J]. 中国抗生素杂志,2022,47(6):550-555.
[22] 孔奕丹,齐英,崔娜,等. 吴茱萸化学成分及药理作用研究进展[J]. 中医药信息,2023,40(5):79-83,89.
[23] 胡诗宛,沈梦菲,张湘苑,等. 重构本草——瓦楞子[J]. 吉林中医药,2023,43(4):465-467.
[24] Graham DY, Lu H, Yamaoka Y. A report card to grade Helicobacter pylori therapy[J]. Helicobacter, 2007 , 12(4):275-278.
